Glaxosmithkline Share News (GSK)

UPDATE 1-U.S. top court rejects GSK bid to throw out racketeering lawsuits

(Adds details on dispute, paragraphs 3-7) By Lawrence Hurley WASHINGTON, June 6 (Reuters) - The U.S. Supreme Court on Monday declined to hear GlaxoSmithKline Plc's bid to throw out lawsuits by union health and welfare funds that said the company's misrepresentation of heart-related ri

U.S. top court rejects GSK bid to throw out racketeering lawsuits

WASHINGTON, June 6 (Reuters) - The U.S. Supreme Court on Monday declined to hear GlaxoSmithKline Plc's bid to throw out lawsuits by union health and welfare funds that said the company's misrepresentation of heart-related risks of its diabetes medication Avandia caused them to pay too much for th

UPDATE 2-Botswana gets GSK's modern HIV drug in largest ever Africa deal

* Tivicay to be used as first-line HIV treatment * 100,000 more Botswanans to receive drug treatment (Adds launch in Gaborone, comment from UNAIDS and U.S. ambassador) By Ben Hirschler LONDON, June 3 (Reuters) - An HIV drug first approved less than three years ago is being rol

Glaxo To Present Sirukumab, Benlysta Data At Rheumatology Congress

GSK's modern HIV drug to be rolled out in Botswana

LONDON, June 3 (Reuters) - An HIV drug first approved less than three years is to be rolled out in Botswana as a first-line core medicine to treat newly diagnosed patients under a contract agreed between the government and ViiV Healthcare. ViiV, which is majority-owned by GlaxoSmithKline, s

Reuters Business News Schedule at 1230 GMT/0830 AM ET

Editor: Sonya Hepinstall +44 207 542 3479 Global Picture Desk: +65 6870 3775 Global Graphics Desk: +65 6870 3595 (All times GMT / ET) Receive this schedule by email: http://mediaexpress.reuters.com TOP STORIES ECB keeps rates unchanged, may raise inflatio

UPDATE 1-GSK seeks lead in triple lung drug market with 2016 filing plan

* U.S. filing by end 2016 vs first half 2018 seen previously * Rivals in triple drug space include AstraZeneca, Novartis (Adds more details on competitive market) By Ben Hirschler LONDON, June 2 (Reuters) - GlaxoSmithKline moved to consolidate its lead in a new class of three-

GlaxoSmithKline brings forward COPD application in US by over a year

(ShareCast News) - GlaxoSmithKline has, after discussions with the US regulator, accelerated the new drug application for its daily closed triple therapy for chronic obstructive pulmonary disease (COPD). GSK and its partner in the drug, Innoviva, now expect to make the US regulatory submission befor

GSK to file 3-in-1 lung drug for U.S. approval this year

LONDON, June 2 (Reuters) - GlaxoSmithKline said on Thursday it now expects to file its new three-in-one inhaled lung drug for U.S. approval by the end of 2016, rather than the first half of 2018 as previously expected, in a boost for its pivotal respiratory business. The so-called "closed t

GlaxoSmithKline Brings US Drug Application For COPD Therapy Forward

Anti-graft group says drugmakers failing to tackle corruption

LONDON, June 2 (Reuters) - The global pharmaceuticals industry remains open to corruption abuse, despite a raft of scandals in recent years, with both companies and governments failing to tackle the issue adequately, according to Transparency International. The anti-corruption advocacy grou

LONDON MARKET CLOSE: UK Shares Dragged Down By Commodity Weakness

How Wellcome and Gates charities profit from helping biotech

* Wellcome firm gets approval for cancer imaging agent * First product from Wellcome Trust in two decades * Follows $80 mln biotech windfall for Gates foundation By Ben Hirschler LONDON, May 30 (Reuters) - The Wellcome Trust medical charity is to profit from U.S. approval

New incentives needed to develop antibiotics to fight superbugs

(Repeats May 27 story with no changes) By Bill Berkrot NEW YORK, May 27 (Reuters) - Drugmakers are renewing efforts to develop medicines to fight emerging antibiotic-resistant bacteria, but creating new classes of drugs on the scale needed is unlikely to happen without new financial

New incentives needed to develop antibiotics to fight superbugs

By Bill Berkrot NEW YORK, May 27 (Reuters) - Drugmakers are renewing efforts to develop medicines to fight emerging antibiotic-resistant bacteria, but creating new classes of drugs on the scale needed is unlikely to happen without new financial incentives to make the effort worth the inves